Literature DB >> 27261520

68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.

Wolfgang P Fendler1, Dorothea F Schmidt2, Vera Wenter2, Kolja M Thierfelder3, Christian Zach2, Christian Stief4,5, Peter Bartenstein2,5, Thomas Kirchner6, Franz J Gildehaus2, Christian Gratzke4,5, Claudius Faber6.   

Abstract

We evaluated the accuracy of PET/CT with 68Ga-PSMA-HBED-CC-a 68Ga-conjugated ligand of human prostate-specific membrane antigen (PSMA)-to localize cancer in the prostate and surrounding tissue at initial diagnosis.
METHODS: Twenty-one patients with biopsy-proven prostate cancer underwent 68Ga-PSMA-HBED-CC (68Ga-PSMA) PET/CT at a median of 4 d (range, 0-47 d) before radical prostatectomy. Based on a 6-segment model, the Gleason score and proportion of tumor tissue within each segment (segmental tumor burden, or STB) as determined by histopathology (STBHP) were correlated with SUVmax and STB as determined by different SUV cutoffs for 68Ga-PSMA PET (STBPET1-6). Furthermore, the involvement of seminal vesicles and other extracapsular extension were assessed by histopathology and PET/CT.
RESULTS: Histopathology-positive segments (n = 100 of 126; 79%) demonstrated a significantly higher mean ± SD SUVmax (11.8 ± 7.6) than histopathology-negative segments (4.9 ± 2.9; P < 0.001). Receiver-operating-characteristic analysis revealed an optimal SUVmax cutoff of 6.5 for discrimination of histopathology-positive segments from histopathology-negative segments (area under the curve, 0.84; P < 0.001), which gave 67% sensitivity, 92% specificity, a 97% positive predictive value, a 42% negative predictive value, and 72% accuracy. STBPET3 as determined by (2 × blood SUV) + (2 × SD) correlated best with STBHP (Pearson ρ = 0.68; P < 0.001; mean difference ± SD, 19% ± 15%). PET/CT correctly detected invasion of seminal vesicles (n = 11 of 21 patients; 52%) with 86% accuracy and tumor spread through the capsule (n = 12; 57%) with 71% accuracy.
CONCLUSION: 68Ga-PSMA PET/CT accurately detected the location and extent of primary prostate cancer. Our preliminary findings warrant further investigation of 68Ga-PSMA PET/CT in conjunction with needle biopsy.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  PET; PSMA; biopsy; prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27261520     DOI: 10.2967/jnumed.116.172627

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  62 in total

Review 1.  Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.

Authors:  Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll
Journal:  J Nucl Med       Date:  2018-12-07       Impact factor: 10.057

2.  Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.

Authors:  Liran Domachevsky; Hanna Bernstine; Natalia Goldberg; Meital Nidam; Onofrio A Catalano; David Groshar
Journal:  Eur Radiol       Date:  2019-07-22       Impact factor: 5.315

3.  Reply to Rahbar K et al.

Authors:  Madhav Prasad Yadav; Sanjana Ballal; Madhavi Tripathi; Chandrasekhal Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-01       Impact factor: 9.236

4.  Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.

Authors:  Liran Domachevsky; Natalia Goldberg; Hanna Bernstine; Meital Nidam; David Groshar
Journal:  Eur Radiol       Date:  2018-05-30       Impact factor: 5.315

5.  18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.

Authors:  Baris Turkbey; Esther Mena; Liza Lindenberg; Stephen Adler; Sandra Bednarova; Rose Berman; Anita T Ton; Yolanda McKinney; Philip Eclarinal; Craig Hill; George Afari; Sibaprasad Bhattacharyya; Ronnie C Mease; Maria J Merino; Paula M Jacobs; Bradford J Wood; Peter A Pinto; Martin G Pomper; Peter L Choyke
Journal:  Clin Nucl Med       Date:  2017-10       Impact factor: 7.794

6.  68Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results.

Authors:  Chen Liu; Teli Liu; Zhongyi Zhang; Ning Zhang; Peng Du; Yong Yang; Yiqiang Liu; Wei Yu; Nan Li; Michael A Gorin; Steven P Rowe; Hua Zhu; Kun Yan; Zhi Yang
Journal:  J Nucl Med       Date:  2020-02-07       Impact factor: 10.057

Review 7.  Advances in prostate-specific membrane antigen PET of prostate cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  Curr Opin Oncol       Date:  2018-05       Impact factor: 3.645

8.  64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer.

Authors:  Teli Liu; Chen Liu; Zhongyi Zhang; Ning Zhang; Xiaoyi Guo; Lei Xia; Jinquan Jiang; Qing Xie; Kun Yan; Steven P Rowe; Hua Zhu; Zhi Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-25       Impact factor: 9.236

Review 9.  Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.

Authors:  Harshad R Kulkarni; Aviral Singh; Thomas Langbein; Christiane Schuchardt; Dirk Mueller; Jingjing Zhang; Coline Lehmann; Richard P Baum
Journal:  Br J Radiol       Date:  2018-06-01       Impact factor: 3.039

Review 10.  The very-high-risk prostate cancer: a contemporary update.

Authors:  R Mano; J Eastham; O Yossepowitch
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-09-13       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.